IKT - Inhibikase Therapeutics, Inc. News

Discover

IKT

Inhibikase Therapeutics, Inc.

1.94

2 x 1.52

2 x 2.45

bid

ask

0.09

4.43%

2 @ 04:00 PM

2.00 +0.06 (3.09%)

Ytd	-5.37%
1y	-0.51%

1.91

day range

2.10

1.33

52 week range

2.26

Open	2.02	Prev Close	2.03	Low	1.91	High	2.10	Mkt Cap	256.14M
Vol	913.99K	Avg Vol	848.78K	EPS	-0.44	P/E	N/A	Forward P/E	-11.84
Beta	1.12	Short Ratio	0.17	Inst. Own	11.62%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	05-12	50-d Avg	1.80	200-d Avg	1.71	1yr Est	7.00

IKT News

benzinga.com

Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Ta

Oppenheimer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Outperform rating an

benzinga.com

Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.10) per share which beat the a

benzinga.com

Inhibikase Therapeutics Says First Patient Enrolled In Pivotal Phase 3 Study IMPROVE-PAH For Treatme

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-s

benzinga.com

Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.10) per share which beat the a

benzinga.com

Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Ta

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Inhibikase Therapeutics (NASDAQ:I

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com

B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Tar

B of A Securities analyst Jason Zemansky initiates coverage on Inhibikase Therapeutics (NASDAQ:IK

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Inhibikase Therapeutics (NASDAQ:IKT) w

benzinga.com

12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga.com

Inhibikase Therapeutics Files SEC Prospectus To Raise Up To $185M Through Existing ATM Program

On December 19, 2025, Inhibikase Therapeutics, Inc. (the "Company") filed with the Securitie

benzinga.com

Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Pr

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT

benzinga.com

12 Health Care Stocks Moving In Friday's Pre-Market Session

benzinga.com

Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

benzinga.com

Inhibikase Therapeutics Announces Common Stock Offering; Terms Not Disclosed

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ("Inhibikase" or "Company"), a clinical-

benzinga.com

12 Health Care Stocks Moving In Thursday's After-Market Session

benzinga.com

Inhibikase Therapeutics Announces Plans To Advance Its PAH Therapeutic Candidate, IKT-001, Into A Gl

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-s

benzinga.com

Inhibikase Therapeutics Q3 EPS $(0.13), Inline

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.13) per share which met the an

benzinga.com

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

Inhibikase Therapeutics Q2 EPS $(0.11) Misses $(0.09) Estimate

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which missed the

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com

Inhibikase Therapeutics Files For Mixed Shelf Of Up To $300M

https://www.sec.gov/Archives/edgar/data/1750149/000119312525143738/d77556ds3.htm

benzinga.com

Inhibikase Therapeutics Q1 EPS $(0.15) Misses $(0.12) Estimate

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.15) per share which missed the

benzinga.com

HC Wainwright & Co. Reiterates Neutral on Inhibikase Therapeuticsto Neutral

HC Wainwright & Co. analyst Edward White reiterates Inhibikase Therapeutics (NASDAQ:IKT) from

benzinga.com

Inhibikase Therapeutics FY 2024 GAAP EPS $(1.16) Misses $(0.90) Estimate

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(1.16) per share which missed the

benzinga.com

This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

benzinga.com

HC Wainwright & Co. Downgrades Inhibikase Therapeutics to Neutral

HC Wainwright & Co. analyst Edward White downgrades Inhibikase Therapeutics (NASDAQ:IKT) from

benzinga.com

12 Health Care Stocks Moving In Thursday's Pre-Market Session

benzinga.com

Inhibikase Therapeutics Q3 2024 GAAP EPS $(0.65) Misses $(0.37) Estimate

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.65) per share which missed the

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

benzinga.com

Jefferies Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $

Jefferies analyst Dennis Ding initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a B

benzinga.com

Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

benzinga.com

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com

HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Lowers Price Target to $5

HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with

benzinga.com

Dow Surges 350 Points; US Crude Oil Stocks Increase

benzinga.com

12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com

Crude Oil Edges Lower; US Wholesale Inventories Rise 0.1% In August

benzinga.com

Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today

Inhibikase Therapeutics shares are trading higher by 50% during Wednesday's session. The company

benzinga.com

Dow Jumps Over 100 Points; Helen Of Troy Posts Upbeat Q2 Results

benzinga.com

Inhibikase Therapeutics Announces Pricing Of $110M Private Placement To Advance IkT-001Pro, Into A L

-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds,

benzinga.com

HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Lowers Price Target to $15

HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with

benzinga.com

Inhibikase Therapeutics Q2 EPS $(0.66) Beats $(0.67) Estimate

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.66) per share which beat the a

benzinga.com

HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Lowers Price Target to $23

HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with

benzinga.com

Inhibikase Therapeutics Q1 2024 GAAP EPS $(0.73) Beats $(0.79) Estimate, Cash $9.7M

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.73) per share which beat the a

benzinga.com

Inhibikase Therapeutics Announces Request For Withdrawal of S-1 Registration Statement; No Securitie

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-s

benzinga.com

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes For IkT-001Pro For Pulmonary Arteri

- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity